蒂莫辛β4作为阿尔茨海默病干预目标,使用人类大脑器官被确定
Peng-Ming Zeng1, Xin-Yao Sun2, Yang Li1
1School of Life Science and Technology & State Key Laboratory of Advanced Medical Materials and Devices, ShanghaiTech University, Shanghai 201210, China.
Stem cell reports
|August 15, 2025
概括
这项研究发现,在家族性阿尔茨海默病 (AD) 中,胆素β4 (Tβ4) 水平下降. 在AD模型中,补充Tβ4挽救了神经发育缺陷,并减少了粉样蛋白-β的产生.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 细胞生物学 细胞生物学
背景情况:
- 阿尔茨海默病 (AD) 的发育起源受到争议.
- 家族性AD (fAD) 涉及粉样蛋白前体蛋白 (APP) 的突变.
研究的目的:
- 用大脑器官来研究fAD中的细胞变化.
- 为了确定AD的潜在治疗点.
主要方法:
- 从诱导多能干细胞 (iPSC) 产生的脑器官,具有与fAD相关的APP突变.
- 分析细胞状态,包括神经元分化,衰老和粉样β (Aβ) 生产.
- 在有机体和5xfAD小鼠模型中评估了蒂莫辛β4 (Tβ4) 的治疗潜力.
主要成果:
- 与对照组相比,fAD有机体显示成熟神经元减少,细胞衰老增加,Aβ生产增加.
- 编码Tβ4 (TMSB4X) 基因的表达在fAD有机体和AD患者神经元中显著下降.
- 在fAD有机体和5xfAD小鼠中,Tβ4治疗挽救了神经发育缺陷,并减少了Aβ形成.
结论:
- Tβ4作为抗阿兹海默症病理的神经保护因子.
- 在AD中,Tβ4可能会减轻神经发生变化和Aβ产生.
- Tβ4代表了阿尔茨海默病干预的潜在治疗策略.
更多相关视频
06:22A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid
Published on: September 3, 2021
3.7K
10:19Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
Published on: August 14, 2016
9.4K
相关概念视频
01:22Alzheimer's Disease: Treatment
261
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
261
01:26Alzheimer's Disease: Overview
668
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
668